Clinical progression in Parkinson disease and the neurobiology of axons
Identifieur interne : 000201 ( Main/Corpus ); précédent : 000200; suivant : 000202Clinical progression in Parkinson disease and the neurobiology of axons
Auteurs : Hsiao-Chun Cheng ; Christina M. Ulane ; Robert E. BurkeSource :
- Annals of Neurology [ 0364-5134 ] ; 2010-06.
Abstract
Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725
Url:
DOI: 10.1002/ana.21995
Links to Exploration step
ISTEX:11E89DC212E899EE314D8FFAFF49B72B683F05FCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical progression in Parkinson disease and the neurobiology of axons</title><author><name sortKey="Cheng, Hsiao Hun" sort="Cheng, Hsiao Hun" uniqKey="Cheng H" first="Hsiao-Chun" last="Cheng">Hsiao-Chun Cheng</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Ulane, Christina M" sort="Ulane, Christina M" uniqKey="Ulane C" first="Christina M." last="Ulane">Christina M. Ulane</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Burke, Robert E" sort="Burke, Robert E" uniqKey="Burke R" first="Robert E." last="Burke">Robert E. Burke</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:11E89DC212E899EE314D8FFAFF49B72B683F05FC</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/ana.21995</idno><idno type="url">https://api.istex.fr/document/11E89DC212E899EE314D8FFAFF49B72B683F05FC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000201</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical progression in Parkinson disease and the neurobiology of axons</title><author><name sortKey="Cheng, Hsiao Hun" sort="Cheng, Hsiao Hun" uniqKey="Cheng H" first="Hsiao-Chun" last="Cheng">Hsiao-Chun Cheng</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Ulane, Christina M" sort="Ulane, Christina M" uniqKey="Ulane C" first="Christina M." last="Ulane">Christina M. Ulane</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Burke, Robert E" sort="Burke, Robert E" uniqKey="Burke R" first="Robert E." last="Burke">Robert E. Burke</name><affiliation><mods:affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06">2010-06</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="715">715</biblScope><biblScope unit="page" to="725">725</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">11E89DC212E899EE314D8FFAFF49B72B683F05FC</idno><idno type="DOI">10.1002/ana.21995</idno><idno type="ArticleID">ANA21995</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hsiao‐Chun Cheng PhD</name><affiliations><json:string>Department of Neurology, Columbia University Medical Center, New York, NY</json:string></affiliations></json:item><json:item><name>Christina M. Ulane MD, PhD</name><affiliations><json:string>Department of Neurology, Columbia University Medical Center, New York, NY</json:string></affiliations></json:item><json:item><name>Robert E. Burke MD</name><affiliations><json:string>Department of Neurology, Columbia University Medical Center, New York, NY</json:string><json:string>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</json:string></affiliations></json:item></author><articleId><json:string>ANA21995</json:string></articleId><language><json:string>eng</json:string></language><abstract>Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725</abstract><qualityIndicators><score>7.784</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1528</abstractCharCount><pdfWordCount>6542</pdfWordCount><pdfCharCount>40798</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>232</abstractWordCount></qualityIndicators><title>Clinical progression in Parkinson disease and the neurobiology of axons</title><genre><json:string>article</json:string></genre><host><volume>67</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>11</total><last>725</last><first>715</first></pages><issn><json:string>0364-5134</json:string></issn><issue>6</issue><subject><json:item><value>Point of View</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/ana.21995</json:string></doi><id>11E89DC212E899EE314D8FFAFF49B72B683F05FC</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/11E89DC212E899EE314D8FFAFF49B72B683F05FC/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/11E89DC212E899EE314D8FFAFF49B72B683F05FC/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/11E89DC212E899EE314D8FFAFF49B72B683F05FC/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Clinical progression in Parkinson disease and the neurobiology of axons</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note>NIH (National Institute of Neurological Disorders and Stroke) - No. NS26836; No. NS38370;</note><note>Parkinson's Disease Foundation</note><note>RJG Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Clinical progression in Parkinson disease and the neurobiology of axons</title><author><persName><forename type="first">Hsiao‐Chun</forename><surname>Cheng</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation></author><author><persName><forename type="first">Christina M.</forename><surname>Ulane</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation></author><author><persName><forename type="first">Robert E.</forename><surname>Burke</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, Room 306, Black Building, Columbia University, 650 West 168th Street, New York, NY 10032</p></note><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation><affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06"></date><biblScope unit="volume">67</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="715">715</biblScope><biblScope unit="page" to="725">725</biblScope></imprint></monogr><idno type="istex">11E89DC212E899EE314D8FFAFF49B72B683F05FC</idno><idno type="DOI">10.1002/ana.21995</idno><idno type="ArticleID">ANA21995</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Point of View</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-09-15">Received</change><change when="2010-01-29">Registration</change><change when="2010-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/11E89DC212E899EE314D8FFAFF49B72B683F05FC/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/ana.v67:6</doi><numberingGroup><numbering type="journalVolume" number="67">67</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2010-06">June 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="60" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.21995</doi><idGroup><id type="unit" value="ANA21995"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Point of View</title><title type="tocHeading1">Point of View</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2009-09-15"></event><event type="manuscriptRevised" date="2010-01-19"></event><event type="manuscriptAccepted" date="2010-01-29"></event><event type="firstOnline" date="2010-05-26"></event><event type="publishedOnlineFinalForm" date="2010-05-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.27 mode:FullText" date="2010-12-11"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">715</numbering><numbering type="pageLast">725</numbering></numberingGroup><correspondenceTo>Department of Neurology, Room 306, Black Building, Columbia University, 650 West 168th Street, New York, NY 10032</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA21995.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="80"></count><count type="wordTotal" number="7347"></count></countGroup><titleGroup><title type="main" xml:lang="en">Clinical progression in Parkinson disease and the neurobiology of axons</title><title type="short" xml:lang="en">PD and Neurobiology of Axons</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Hsiao‐Chun</givenNames><familyName>Cheng</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christina M.</givenNames><familyName>Ulane</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Robert E.</givenNames><familyName>Burke</familyName><degrees>MD</degrees></personName><contactDetails><email>rb43@columbia.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia University Medical Center, New York, NY</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</unparsedAffiliation></affiliation></affiliationGroup><fundingInfo><fundingAgency>NIH (National Institute of Neurological Disorders and Stroke)</fundingAgency><fundingNumber>NS26836</fundingNumber><fundingNumber>NS38370</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Parkinson's Disease Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>RJG Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Clinical progression in Parkinson disease and the neurobiology of axons</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PD and Neurobiology of Axons</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Clinical progression in Parkinson disease and the neurobiology of axons</title></titleInfo><name type="personal"><namePart type="given">Hsiao‐Chun</namePart><namePart type="family">Cheng</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christina M.</namePart><namePart type="family">Ulane</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert E.</namePart><namePart type="family">Burke</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Columbia University Medical Center, New York, NY</affiliation><affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY</affiliation><description>Correspondence: Department of Neurology, Room 306, Black Building, Columbia University, 650 West 168th Street, New York, NY 10032</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-06</dateIssued><dateCaptured encoding="w3cdtf">2009-09-15</dateCaptured><dateValid encoding="w3cdtf">2010-01-29</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="tables">1</extent><extent unit="references">80</extent><extent unit="words">7347</extent></physicalDescription><abstract lang="en">Despite tremendous growth in recent years in our knowledge of the molecular basis of Parkinson disease (PD) and the molecular pathways of cell injury and death, we remain without therapies that forestall disease progression. Although there are many possible explanations for this lack of success, one is that experimental therapeutics to date have not adequately focused on an important component of the disease process, that of axon degeneration. It remains unknown what neuronal compartment, either the soma or the axon, is involved at disease onset, although some have proposed that it is the axons and their terminals that take the initial brunt of injury. Nevertheless, this concept has not been formally incorporated into many of the current theories of disease pathogenesis, and it has not achieved a wide consensus. More importantly, in view of growing evidence that the molecular mechanisms of axon degeneration are separate and distinct from the canonical pathways of programmed cell death that mediate soma destruction, the possibility of early involvement of axons in PD has not been adequately emphasized as a rationale to explore the neurobiology of axons for novel therapeutic targets. We propose that ongoing degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to forestall disease progression will benefit from a new focus on the distinct mechanisms of axon degeneration. ANN NEUROL 2010;67:715–725</abstract><note type="funding">NIH (National Institute of Neurological Disorders and Stroke) - No. NS26836; No. NS38370; </note><note type="funding">Parkinson's Disease Foundation</note><note type="funding">RJG Foundation</note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Point of View</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>715</start><end>725</end><total>11</total></extent></part></relatedItem><identifier type="istex">11E89DC212E899EE314D8FFAFF49B72B683F05FC</identifier><identifier type="DOI">10.1002/ana.21995</identifier><identifier type="ArticleID">ANA21995</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000201 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000201 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:11E89DC212E899EE314D8FFAFF49B72B683F05FC
|texte= Clinical progression in Parkinson disease and the neurobiology of axons
}}
| This area was generated with Dilib version V0.6.23. |  |